Wakamoto Pharmaceutical Co.,Ltd. (TYO:4512)

Market Cap	11.59B +54.9%
Revenue (ttm)	9.43B -2.5%
Net Income	-222.00M
EPS	-6.38
Shares Out	34.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	3.00 (0.95%)
Ex-Dividend Date	Mar 30, 2026

Volume	158,500
Average Volume	246,485
Open	325.00
Previous Close	315.00
Day's Range	325.00 - 335.00
52-Week Range	270.00 - 371.00
Beta	0.63
RSI	54.34
Earnings Date	Feb 5, 2026

About Wakamoto Pharmaceutical

Wakamoto Pharmaceutical Co.,Ltd. engaged in the manufacture and sale of pharmaceuticals, medical devices, and health food in Japan. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation, as well as Wakamoto Intestinal Remedy drug. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 403
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4512

Financial Performance

In fiscal year 2012, Wakamoto Pharmaceutical's revenue was 9.43 billion, a decrease of -2.45% compared to the previous year's 9.67 billion. Losses were -222.00 million, -47.76% less than in 2011.